Investment Highlights
1H19 revenue growth of 22.9% vs previous corresponding period. EBITDA profitability expected for FY19
- Vertically integrated – Can maximise margins and control supply
- Favourable industry dynamics – Chinese Vitamin and Dietary Supplement demand forecast >US$22 billion by 2020
- Experienced management team – deep understanding of China market and distribution network
- Wholly owned online distribution platform – 5,000 product lines, real-time demand trend analysis
- State of the art manufacturing facility – TGA licensed with excess capacity for anticipated growth
- Pipeline of accretive acquisitions – looking to acquire more profitable brands that can leverage existing manufacturing facility and overseas distribution networks
- Growing pipeline of own products, 9 with China Inspection and Quarantine certification (CIQ) and expecting CIQ for 5 new products
- Experience and knowledge of CIQ registration process
- Ability to innovate – In-house R&D team has the ability to analyse demand, create and bring products to market quickly
- No debt – 1H19 closing net cash of A$7.8m
To view Presentation please download PDF attached:
Download this document
